Precision oncology: 2023 in review Review
| Authors: | Murciano-Goroff, Y. R.; Suehnholz, S. P.; Drilon, A.; Chakravarty, D. |
| Review Title: | Precision oncology: 2023 in review |
| Abstract: | Summary: This article presents a review of recent major advances in precision oncology and the future implications of these advances, specifying the iterative progress achieved from the end of 2022 through 2023. We discuss the different classes of precision oncology drugs and associated biomarkers as well as the improvements in clinical trial design that have enabled the efficient testing of these drugs. © 2023 The Authors; Published by the American Association for Cancer Research. |
| Keywords: | cancer chemotherapy; protein expression; treatment response; gene mutation; overall survival; genetics; prednisone; monotherapy; treatment duration; paclitaxel; glioma; endometrium cancer; neoplasm; neoplasms; colorectal cancer; biological marker; carboplatin; cancer immunotherapy; progression free survival; breast cancer; protein degradation; epidermal growth factor receptor 2; food and drug administration; drug development; brca1 protein; brca2 protein; oncology; proteomics; cetuximab; fibroblast growth factor receptor 3; tumor marker; carcinogenesis; panitumumab; prostate cancer; prednisolone; t lymphocyte receptor; antigen presentation; myelodysplastic syndrome; microsatellite instability; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; atm protein; medical oncology; pancreas adenocarcinoma; tumor immunity; oligodendroglioma; checkpoint kinase 2; bile duct carcinoma; disease control; trastuzumab; cytokine release; rectum cancer; astrocytoma; atr protein; b raf kinase; biliary tract cancer; fibroblast growth factor receptor 1; rad51 protein; fulvestrant; pertuzumab; olaparib; personalized medicine; hla system; non small cell lung cancer; tumor microenvironment; molecularly targeted therapy; abiraterone; isocitrate dehydrogenase 1; plasma cell granuloma; fanconi anemia group a protein; acute myeloid leukemia; crizotinib; fibroblast growth factor receptor 4; toll like receptor 7; toll like receptor 8; dabrafenib; trametinib; isocitrate dehydrogenase 2; enzalutamide; quizartinib; recombination repair; humans; human; article; precision medicine; binimetinib; alectinib; encorafenib; biomarkers, tumor; personalized cancer therapy; mutl protein homolog 1; antibody drug conjugate; talazoparib; tumor mutational burden; ivosidenib; vorasidenib; double strand break repair protein mre11; partner and localizer of brca2; repotrectinib; capivasertib; tucatinib; sotorasib; dostarlimab; adagrasib; elacestrant; abiraterone acetate plus niraparib; lirafugratinib; proteolysis targeting chimera |
| Journal Title: | Cancer Discovery |
| Volume: | 13 |
| Issue: | 12 |
| ISSN: | 2159-8274 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2023-12-01 |
| Start Page: | 2525 |
| End Page: | 2531 |
| Language: | English |
| DOI: | 10.1158/2159-8290.Cd-23-1194 |
| PUBMED: | 38084089 |
| PROVIDER: | scopus |
| PMCID: | PMC10715685 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding author is MSK author: Debyani Chakravarty -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
86Chakravarty -
632Drilon -
20Suehnholz
Related MSK Work